GleamWall
中文EN

AUTL Autolus Therapeutics plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1730463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY168.8%
TTM net income YoY-13.9%
TTM EPS YoY-15.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin35.8%
Operating margin-159.6%
Net margin-186.4%
FCF margin-131.1%
EBITDA margin-153.1%

Returns

ROE-174.9%
ROA-43.2%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets94.8%
Debt / equity0.00x
Current ratio3.72x
Interest coverage-4.79x

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$41.24M$45.69M$26.22M$24.29M$21.19M$20.92M$8.98M$29,000
Cost of revenue$17.93M$20.47M$24.57M$25.33M$28.64M$24.45M$17.95M$11.39M
Gross profit$23.31M$25.22M$1.65M-$1.04M-$7.45M-$3.52M-$8.97M-$11.36M
R&D expense$30.90M$27.90M$21.21M$35.63M$27.89M$27.43M$26.73M$30.83M
SG&A expense$35.95M$41.16M$39.95M$35.80M$36.28M$30.27M$29.54M$33.68M
Operating income-$43.53M-$43.84M-$59.51M-$72.47M-$71.62M-$61.22M-$65.24M-$75.86M
Interest expense$14.53M-$2.67M$11.12M$22.84M$10.52M-$6.83M$10.14M-$30.84M
Pretax income-$55.58M-$38.65M-$70.73M-$91.52M-$78.59M-$47.52M-$67.94M-$26.14M
Income tax-$489,000$465,000$863,000-$1.18M$532,000$397,000$2.23M$1.46M
Net income-$55.09M-$39.11M-$71.60M-$90.33M-$79.12M-$47.92M-$70.16M-$27.61M
EBITDA-$41.13M-$41.64M-$57.30M-$70.32M-$69.52M-$59.12M-$63.25M-$73.95M
EPS (basic)-0.21-0.15-0.27—-0.30-0.18-0.26—
EPS (diluted)-0.21-0.15-0.27—-0.30-0.18-0.26—
Weighted avg. shares (diluted)266.20M266.16M266.14M—266.14M266.14M266.13M—
Balance sheet
Cash & equivalents$245.41M$171.41M$130.93M$104.13M$86.12M$123.83M$95.80M$228.80M
Short-term investments$2.97M$30.22M$98.51M$196.58M$281.29M$330.45M$420.78M$360.64M
Receivables$38.00M$44.39M$27.66M$24.02M———$15,000
Inventory$35.02M$33.43M$33.23M$33.21M$27.72M$23.94M$14.65M$4.14M
Current assets$366.78M$336.09M$368.83M$435.92M$514.58M$574.25M$615.77M$660.93M
PP&E, net$59.66M$60.52M$61.91M$63.56M$66.85M$66.47M$57.97M$49.55M
Intangibles$18.07M$18.53M$18.98M$19.81M$20.28M$12.93M$12.47M$12.37M
Total assets$523.06M$493.23M$527.07M$589.07M$661.95M$720.98M$746.34M$782.73M
Current liabilities$98.65M$68.79M$63.60M$73.44M$83.07M$68.15M$66.61M$60.74M
Total liabilities$495.66M$418.39M$418.24M$410.94M$396.50M$374.52M$375.23M$355.40M
Shareholders' equity$27.40M$74.84M$108.83M$178.13M$265.45M$346.46M$371.11M$427.32M
Cash flow statement
Operating cash flow-$18.53M-$25.07M-$65.32M-$67.32M-$67.90M-$72.78M-$75.56M-$37.93M
Capital expenditure$1.25M$913,000$2.69M-$885,000$4.41M$7.28M$8.24M$11.11M
Free cash flow-$19.78M-$25.98M-$68.00M-$66.44M-$72.31M-$80.06M-$83.81M-$49.05M
Investing cash flow$25.99M$67.90M$96.15M$86.54M$35.55M$95.92M-$59.55M-$383.59M
Financing cash flow$67.33M-$2.14M-$2.06M-$1.80M-$1.77M-$768,000$0$30.01M
Depreciation & amortization$2.40M$2.20M$2.21M$2.14M$2.10M$2.10M$1.99M$1.92M
Stock-based compensation$2.73M$4.59M$3.56M$3.44M$3.83M$4.29M$2.87M$6.23M

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.